CA3080427A1 - Vaccin contre le virus de la leucemie feline - Google Patents
Vaccin contre le virus de la leucemie feline Download PDFInfo
- Publication number
- CA3080427A1 CA3080427A1 CA3080427A CA3080427A CA3080427A1 CA 3080427 A1 CA3080427 A1 CA 3080427A1 CA 3080427 A CA3080427 A CA 3080427A CA 3080427 A CA3080427 A CA 3080427A CA 3080427 A1 CA3080427 A1 CA 3080427A1
- Authority
- CA
- Canada
- Prior art keywords
- feline
- felv
- virus
- vaccine
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010043839 feline leukemia virus vaccine Proteins 0.000 title description 2
- 241000714165 Feline leukemia virus Species 0.000 claims abstract description 172
- 229960005486 vaccine Drugs 0.000 claims abstract description 145
- 238000000034 method Methods 0.000 claims abstract description 11
- 108091007433 antigens Proteins 0.000 claims description 144
- 102000036639 antigens Human genes 0.000 claims description 144
- 239000000427 antigen Substances 0.000 claims description 108
- 241000710929 Alphavirus Species 0.000 claims description 103
- 239000002245 particle Substances 0.000 claims description 98
- 241000282324 Felis Species 0.000 claims description 73
- 239000012634 fragment Substances 0.000 claims description 59
- 230000000890 antigenic effect Effects 0.000 claims description 58
- 241000714201 Feline calicivirus Species 0.000 claims description 56
- 101800001271 Surface protein Proteins 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 49
- 108090000288 Glycoproteins Proteins 0.000 claims description 44
- 102000003886 Glycoproteins Human genes 0.000 claims description 44
- 230000002163 immunogen Effects 0.000 claims description 39
- 244000052769 pathogen Species 0.000 claims description 26
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 claims description 22
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 claims description 22
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 230000002238 attenuated effect Effects 0.000 claims description 22
- 230000001717 pathogenic effect Effects 0.000 claims description 22
- 241000701915 Feline panleukopenia virus Species 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 17
- 241000724653 Borna disease virus Species 0.000 claims description 16
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 claims description 16
- 241000711475 Feline infectious peritonitis virus Species 0.000 claims description 16
- 241000701925 Feline parvovirus Species 0.000 claims description 16
- 241000446432 Feline pneumovirus Species 0.000 claims description 15
- 241000712461 unidentified influenza virus Species 0.000 claims description 13
- 241000725579 Feline coronavirus Species 0.000 claims description 12
- 241001647374 Chlamydia felis Species 0.000 claims description 11
- 241000713800 Feline immunodeficiency virus Species 0.000 claims description 9
- 206010051497 Rhinotracheitis Diseases 0.000 claims description 8
- 230000001681 protective effect Effects 0.000 claims description 7
- 230000036039 immunity Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 4
- 230000006806 disease prevention Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 101900302604 Feline leukemia virus Surface protein Proteins 0.000 claims 2
- 239000003223 protective agent Substances 0.000 abstract description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 105
- 241000282326 Felis catus Species 0.000 description 41
- 150000007523 nucleic acids Chemical class 0.000 description 40
- 108020004707 nucleic acids Proteins 0.000 description 39
- 102000039446 nucleic acids Human genes 0.000 description 39
- 238000002255 vaccination Methods 0.000 description 22
- 230000003612 virological effect Effects 0.000 description 20
- 239000013598 vector Substances 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 15
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 229940031348 multivalent vaccine Drugs 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 101710142606 Sliding clamp Proteins 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108090000565 Capsid Proteins Proteins 0.000 description 6
- 102100023321 Ceruloplasmin Human genes 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- 241000710961 Semliki Forest virus Species 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 241000282465 Canis Species 0.000 description 5
- 108091061960 Naked DNA Proteins 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- -1 /or Species 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 241000606660 Bartonella Species 0.000 description 3
- 241001518086 Bartonella henselae Species 0.000 description 3
- 241000588779 Bordetella bronchiseptica Species 0.000 description 3
- 241000446430 Canine pneumovirus Species 0.000 description 3
- 208000002979 Influenza in Birds Diseases 0.000 description 3
- 102400001093 PAK-2p27 Human genes 0.000 description 3
- 241000711798 Rabies lyssavirus Species 0.000 description 3
- 241000287219 Serinus canaria Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 206010064097 avian influenza Diseases 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- PQHQBRJAAZQXHL-GQCOAOBCSA-N 2-(4-iodanyl-2,5-dimethoxyphenyl)ethanamine Chemical compound COC1=CC(CCN)=C(OC)C=C1[125I] PQHQBRJAAZQXHL-GQCOAOBCSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102100021696 Syncytin-1 Human genes 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 108010016981 feline leukemia virus protein p27 Proteins 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282323 Felidae Species 0.000 description 1
- 208000004729 Feline Leukemia Diseases 0.000 description 1
- 101900068883 Feline leukemia virus Envelope glycoprotein Proteins 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 1
- 101100356268 Schizosaccharomyces pombe (strain 972 / ATCC 24843) red1 gene Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001672 cytoproliferative effect Effects 0.000 description 1
- 230000002466 cytosuppressive effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 229960004279 formaldehyde Drugs 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000001038 ionspray mass spectrometry Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108010062490 p27 antigen Proteins 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- UBCKGWBNUIFUST-YHYXMXQVSA-N tetrachlorvinphos Chemical compound COP(=O)(OC)O\C(=C/Cl)C1=CC(Cl)=C(Cl)C=C1Cl UBCKGWBNUIFUST-YHYXMXQVSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne un vaccin contre le virus de la leucémie féline ainsi que des procédés de préparation et des méthodes d'utilisation du vaccin seul, ou en association avec d'autres agents protecteurs.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762582050P | 2017-11-06 | 2017-11-06 | |
| US62/582,050 | 2017-11-06 | ||
| US62/596,508 | 2017-12-08 | ||
| US62/599,401 | 2017-12-15 | ||
| PCT/EP2018/080094 WO2019086646A1 (fr) | 2017-11-06 | 2018-11-05 | Vaccin contre le virus de la leucémie féline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3080427A1 true CA3080427A1 (fr) | 2019-05-09 |
Family
ID=64316486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3080427A Pending CA3080427A1 (fr) | 2017-11-06 | 2018-11-05 | Vaccin contre le virus de la leucemie feline |
Country Status (4)
| Country | Link |
|---|---|
| JP (2) | JP2021501761A (fr) |
| AU (1) | AU2018358077A1 (fr) |
| CA (1) | CA3080427A1 (fr) |
| WO (1) | WO2019086646A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11229699B2 (en) | 2017-11-06 | 2022-01-25 | Intervet Inc. | Feline calicivirus vaccine |
| WO2021228731A1 (fr) | 2020-05-11 | 2021-11-18 | Intervet International B.V. | Vaccin contre le coronavirus 2 du syndrome respiratoire aigu sévère félin |
| US20240000920A1 (en) | 2020-11-12 | 2024-01-04 | Intervet Inc. | Recombinant vectors encoding chimeric coronavirus spike proteins and use thereof |
| CN112852840A (zh) * | 2021-01-20 | 2021-05-28 | 西南民族大学 | 一种牛纽布病毒重组vp1基因、重组蛋白及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2270120T3 (es) * | 2002-09-23 | 2007-04-01 | Mologen Ag | Vacuna contra infecciones causadas por oncovirus tales como el virus de la leucemia felina. |
| AU2005245956B2 (en) | 2004-05-18 | 2011-05-19 | Alphavax, Inc. | TC-83-derived alphavirus vectors, particles and methods |
| US7850977B2 (en) | 2007-06-21 | 2010-12-14 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
| US10004797B2 (en) * | 2010-10-27 | 2018-06-26 | Harrisvaccines, Inc. | Method of rapidly producing improved vaccines for animals |
-
2018
- 2018-11-05 JP JP2020524369A patent/JP2021501761A/ja active Pending
- 2018-11-05 WO PCT/EP2018/080094 patent/WO2019086646A1/fr unknown
- 2018-11-05 CA CA3080427A patent/CA3080427A1/fr active Pending
- 2018-11-05 AU AU2018358077A patent/AU2018358077A1/en active Pending
-
2023
- 2023-08-23 JP JP2023135272A patent/JP2023159327A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018358077A1 (en) | 2020-05-14 |
| JP2023159327A (ja) | 2023-10-31 |
| JP2021501761A (ja) | 2021-01-21 |
| WO2019086646A1 (fr) | 2019-05-09 |
| WO2019086646A8 (fr) | 2020-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3080427A1 (fr) | Vaccin contre le virus de la leucemie feline | |
| US11992526B2 (en) | Rabies virus vaccine | |
| JP7374893B2 (ja) | ネコカリシウイルスワクチン | |
| AU2022209359A1 (en) | Multivalent feline vaccine | |
| US12076392B2 (en) | Feline leukemia virus vaccine | |
| US11730809B2 (en) | Multivalent feline vaccine | |
| RU2784533C2 (ru) | Вакцина против вируса лейкоза кошачьих | |
| RU2792898C2 (ru) | Вакцина против кошачьего калицивируса | |
| RU2782350C2 (ru) | Вакцина против вируса бешенства | |
| US20240269259A1 (en) | Rabies virus vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231106 |
|
| EEER | Examination request |
Effective date: 20231106 |